Obstructive lung diseases and inhaler treatment: results from a national public pragmatic survey by unknown
Braido et al. Respiratory Research 2013, 14:94
http://respiratory-research.com/content/14/1/94RESEARCH Open AccessObstructive lung diseases and inhaler treatment:
results from a national public pragmatic survey
Fulvio Braido1*, Ilaria Baiardini1, Massimo Sumberesi2, Francesco Blasi3 and Giorgio Walter Canonica1Abstract
Background: The opinions held by the general population on obstructive lung disease and inhaler devices could
influence asthma and chronic obstructive pulmonary disorder (COPD) management and treatment adherence.
The aim of the present public pragmatic survey was to evaluate the opinions, beliefs and perceptions of Italian
people with respect to respiratory diseases as well as their perspectives on the use of inhaler devices.
Methods: This survey was conducted on a group of 2,008 individuals forming a representative sample of the Italian
population aged 15 years and over. It was based on personal interviews that were administered in the homes of
the respondents using a structured questionnaire that took approximately 30 minutes.
Results: Awareness of obstructive lung diseases is poor. Asthma, but not COPD, was perceived as a common and
increasingly prevalent disease by the majority of the interviewees. Allergy, pollution and smoking were considered
to be responsible for both of these diseases. The rates at which the respondents claimed to be suffering from
asthma and COPD were lower than expected (4% and 2%, respectively). Inhaled drugs were recognised as the main
treatment by 65% of the respondents. The great majority of respondents attributed positive characteristics to the
inhaler device (e.g., safety, reliability, effectiveness, ease of use and practicality). Compared to people who have
never used inhaler devices, individuals who suffer from asthma or COPD were more confident in their use and
showed a greater belief in their safety, reliability and trustworthiness. People older than 64 years showed less
attention to the properties of these devices.
Conclusions: The present results highlight the need for public interventions aimed at improving awareness of
obstructive lung disease and reveal various potentialities and critical issues for inhaler device usage. Switching of devices
was considered feasible by most of the interviewees, as long as the choice is carefully explained by their physician.Background
Chronic respiratory diseases are among the leading
causes of morbidity and mortality, and the prevalence of
these diseases is expected to increase in the coming
years [1-4]. Data published by the WHO suggest that
hundreds of millions of people currently suffer from
these conditions worldwide [4]. It is estimated that there
are approximately 7 million asthma and COPD patients
in Italy, comprising 11.5% of the general population. The
prevalence of asthma is 6.2%, or a total of approximately
3.7 million patients. COPD has a prevalence of 5.3% (for
a total of approximately 3.3 million cases) [5,6]. Every
year, nearly 300,000 new cases of asthma and COPD are* Correspondence: fulvio.braido@unige.it
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reproduction in any medium, provided the orreported (an estimated incidence of 6%), and there are
approximately 40.000 deaths yearly (6.8%) (22,329 men
and 17,620 women) [7]. Italy spends 14 billion euros
each year on respiratory diseases (equal to 1% of the Ital-
ian GDP); of these costs, 5 billion euros are for direct/in-
direct costs associated with asthma and 9 billion euros
are for direct/indirect costs associated with emphysema
and/or COPD. The weighted per capita cost of asthma
therapy is equal to 1,434 euros, whereas it is 2,723 euros
for COPD [8,9].
Although effective therapies exist for these conditions
[10,11], chronic respiratory diseases are frequently not
adequately treated. One of the main problems is a lack
of adherence to treatment by patients [12-17].
The term ‘compliance’ (the extent to which a person’s
corresponds to physician’s prescription) has been used for
a long time to define the observation of the prescriptionsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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scriptions) by the patient. More recently, the term ‘adher-
ence’ has been preferred over the concept of compliance
because of the authoritative and paternalistic connotations
of the latter one. Adherence has been defined as the extent
to which a person’s behaviour corresponds to the recom-
mendations agreed with a health care provider’. Adher-
ence involves consumer’s choice and is intended to be
non-judgemental, at variance with compliance, which re-
inforces patient passivity and blame [15].
The treatment of these diseases involves the adminis-
tration of drugs using an inhaler device and specific
techniques that the doctor must explain to the patient.
During treatment, the patient may encounter a difficulty
in using the device, leading to under-use and/or misuse
[18,19]. This improper use has inevitable consequences
on both the health of the patient and the entire health
care system [20-22].
Relatively little research has addressed the public
awareness of asthma, COPD and related treatment is-
sues [23-28].
The aim of the present public pragmatic survey is to
evaluate the following:
– opinions, beliefs and perceptions of Italian people
regarding respiratory diseases.
– attitudes, motivations and barriers regarding the use
of inhaler devices.
Methods
This ad hoc survey was conducted on a sample of 2,008
individuals that represented the Italian population aged
15 years and over (52.1 million people).
When choosing the sample size, the need to accommo-
date a maximum margin of sampling error was taken into
account. Considering the sample of 2,008 respondents out
of an overall population of more than 52 million people
aged >15 years, a sampling error of ± 2.88% is reported,
which ensures a confidence level of 99% in the worst-case
scenario of parameter estimation (p = 50%).
The survey was based on personal interviews that were
administered in the homes of the respondents using a
structured questionnaire that took approximately 30 mi-
nutes to complete and the support of a laptop computer
(CAPI system, Computer-Assisted Personal Interviewing).
A total of 130 fully trained interviewers from the na-
tional network of DOXA interviewers who specialise in
face-to-face interviews conducted the survey between
May 22, 2012 and June 3, 2012.
The community under study was divided into sections
or "layers" based on two criteria: the region and size of
the municipality of residence.
The number of interviews conducted in each "layer"
(i.e., in municipalities of Italian regions with populationsof less than 5,000 residents) was calculated to ensure
that the number of interviews was proportional to the
distribution among the various "layers" of communities
under study.
All of the units included in the sample represent a mini-
ature reproduction of the community being considered
(proportional stratified sampling method) according to the
two above-mentioned criteria. The next step was to iden-
tify the sampling units within each "layer" (municipalities,
municipality area and people). Among the municipalities,
certain sampling points to perform the interviews were se-
lected in each layer. An adequate number of polling sta-
tions (each of which corresponds to a specific area of the
town) were selected in each municipality to ensure that all
of the various types of residential areas within the town
(the central areas, peripheral areas and isolated houses)
were represented properly.
The names and addresses of the people to be inter-
viewed were extracted from the electoral roll. People aged
15 to 17 years, who cannot yet register to vote, were se-
lected using the quotas method.
During the processing phase, the data were weighted
and a weight (or weighting factor) was assigned to each
interview to perfectly balance the sample compared to the
reference population. The weighting procedure was per-
formed while considering the following variables: gender
according to age, region according to town amplitude,
education (degree/diploma/middle school/elementary
school) and employment status (working/not working).
Statistical analysis
A descriptive analysis of the answers to the question-
naires was performed, and the χ2 test was used to test
for an association between the questionnaire answers
and membership in a particular group (inhaler users/
non-users or inhaler users younger/older than 64 years).
The relationship between single items and the general
opinion regarding inhaler devices (latent importance)
was evaluated using the Pearson correlation coefficient.
The level of accordance was calculated as the percentage
of patients who agreed with each item.
Results
In total, 2,008 individuals (52% females) were evaluated.
The demographic characteristics of the population are
given in Table 1.
To assess their awareness of the diseases under study,
the respondents were asked whether they had recently
heard of any of several diseases, including asthma, mi-
graines, hypertension, diabetes, osteoporosis, arthrosis,
colitis, hepatitis, celiac disease, glaucoma and COPD. Only
51% and 14% of the interviewees recognised “asthma” and
“COPD”, which ranked fifth and last (eleventh),
respectively.









> 64 yrs. 22
Geographic area Northwest 27
Northeast 19
Centre 20
South and Islands 34
Education Primary and secondary school 50
High school 41
Academic degree 9
Professional condition Employed 47
Unemployed 53
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to the age, both of the pathologies were better known by
individuals who were >45 years old. In particular, the
level of asthma awareness was highest in the 55–64 year
age group (58%), whereas COPD awareness was highest
in the 45–54 year age group (19%). For both diseases,
the level of awareness reported by people under 25 years
of age was the lowest among the age groups (47% for
asthma and 6% for COPD) (Figure 1).Figure 1 Awareness by age.Although 42% of the interviewees reported a medium-
high level of asthma awareness, 14% declared that they
knew nothing about the disease, whereas 33% and 40%
of the respondents reported a poor and a fair knowledge
of it, respectively. The survey revealed a severe lack of
knowledge of COPD; only 13% of the interviewees
reported a medium-high level of COPD awareness,
whereas 47% reported that they knew nothing about the
disease.
With respect to the perception of disease prevalence,
68% of the respondents indicated that asthma is highly
widespread among the population, whereas only 21% indi-
cated the same regarding COPD. Moreover, 50% and 16%
of the sample considered asthma and COPD, respectively,
to be increasing among the population, whereas 22% and
17% answered that the prevalence is stable.
Among the 1038 individuals who had previously stated
they had heard of asthma, children, elderly people and
people living in the city were considered the groups
most likely to be at risk for asthma by 29%, 28% and
28% of the respondents, respectively. Among the 291 re-
spondents who had previously stated they had heard of
COPD, 27% of them considered the elderly to be most
likely to suffer from COPD caused smoking, followed by
people who worked in particular jobs (24%).
Allergies, pollution and smoking were considered to
be the most relevant causes of asthma by 74%, 49% and
42% of the respondents, respectively. The same causes
were also considered as the most likely to lead to the de-
velopment of COPD by 35%, 35% and 49% of the re-
spondents, respectively.
According to the survey, awareness of the disease bur-
den in terms of symptoms was very high (92%) for both
asthma and COPD, as was awareness of the serious im-
pact of the disease on the lives of patients (82% for
asthma and 87% for COPD).
The majority of the respondents (66% for asthma and
50% for COPD) believed that the most frequently used
treatments for both diseases are inhaled drugs.
In the survey, 13% of the respondents indicated that
they either personally suffer or have relatives suffering
from asthma/COPD: 4% suffered from asthma and 2% suf-
fered from COPD, whereas 6% and 1% had at least one
relative suffering from asthma and COPD, respectively.
The survey showed that 65% of asthma/COPD suf-
ferers used an inhaler device (25% regularly, 32% during
the acute phases and 7% only for emergencies), whereas
16% had never used one and 19% had only used one in
the past. Regarding familiarity with the inhaler device,
6% of the sample reported having had a direct experi-
ence with asthma/COPD. However, 24% of the respon-
dents reported an indirect experience with the diseases:
7% had at least one relative suffering from asthma/
COPD (78% of whom used a device), whereas 17% of
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asthma/COPD (70% of whom used a device). Finally,
70% of the sample only had a nominal awareness of the
diseases, as they did not know anyone suffering from
asthma/COPD; of these respondents, 68% had heard
about inhaler devices.
When the patients who use inhaler devices were asked
whether their physician (GP and/or specialist) had
explained to them how the device should be used, 89%
of the respondents answered that they had been given
an adequate and exhaustive explanation, 7% indicated
that the explanation had been too generic and 4% indi-
cated that no explanation had been provided to them.
The entire sample was questioned regarding attitudes
towards inhaler devices in terms of efficacy, practicality
and reliability/safety. The devices were considered to
have a more rapid effect by 76% of the respondents, to
act in a more precise way by 74%, to be more effective
by 68% and to have a more prolonged effect over time
by 50%, relative to other routes of drug administration.
Furthermore, 79% of the respondents indicated that tak-
ing a drug through an inhaler device seems to be more
practical and convenient; the same percentage felt com-
pletely capable of making an inhaler device work, and
73% of the respondents stated that using the inhaler de-
vice made it easier to follow a treatment plan. Moreover,
57% of the sample considered these devices not difficult
to use in a daily routine. Regarding reliability/safety, 80%
of the interviewees considered the devices to be abso-
lutely safe and reliable, whereas 50% believed that taking
a drug through an inhaler device can reduce the risk of
side effects.
Among the respondents, 75% indicated that taking a
drug through an inhaler device is the best solution for
respiratory diseases, 58% indicated that it is also an ex-
cellent solution for non-respiratory disease and 45% only
considered it to be a possible option for less serious dis-
eases. Conversely, 33% of the respondents replied that
using these devices carried the impression of following a
mild treatment.
Considering the use of inhaler devices in relation to
mood, the majority of the sample (74%) indicated that
they felt completely calm and relaxed when thinking
about using one of these devices, 50% did not believe
that using it would contribute to the efficacy of the drug
itself, 30% did not feel comfortable with the idea of using
it and 61% believed that all of these devices are equal.
More than a third of the sample expressed concerns
regarding the hygiene of the device. Conversely, a lower
percentage of respondents expressed concerns regarding
the possibility that the device could contain substances
that are potentially harmful to the environment or
harmful to their health, or that the devices could be
made of harmful materials (23%, 22% and 19%,respectively). Other concerns included problems with
the functioning of the device itself: 33% of the respon-
dents indicated that when using the device, it is not clear
when the drug has been taken, whereas 30% and 28%
believed that the device may not work properly or that
they may use it incorrectly without realising it. However,
79% of the respondents felt confident of their ability to
use the device properly.
Additionally, 72% of the interviewees indicated that
using an inhaler device ensured that they always received
the same dose of the drug; however, 33% of the respon-
dents indicated that using the device introduced the pos-
sibility that some of the drug could be wasted and not
reach the lungs, and 25% of the respondents indicated
that the dosage could be either insufficient or excessive.
The results indicated that 72% of the sample consid-
ered the inhaler device to be suitable for them; 71%
stated that if they had to follow a treatment plan, they
would rather take an inhaled drug rather than pills; 61%
would be willing to use an inhaler device for a long
period of time; and 56% would only be willing to use
such a device for short period of time. Regarding their
willingness to change inhaler devices, 86% of the sample
wished to be informed of exactly how the new device
works, 85% and 60% would change their device if their
physician advised them to do so and 81% preferred to
maintain their current type of inhaler device if they
changed the drug they were taking.
The overall opinion of the respondents on inhaler de-
vices was positive, especially among those who used the
devices (94%), those who had a relative who used one
(94%) and those who had at least heard about them
(90%). The percentage of respondents with a positive
opinion was lower (63%) among those who were not fa-
miliar with the devices.
Strategic areas of intervention needed to improve adher-
ence to inhaler device treatments are reported in Figure 2
and Figure 3.
Table 2 reports the significant differences revealed by
comparing sufferers (6%) to non- sufferers (94%) and in-
terviewees aged ≤64 years (76%) to those >64 years (24%).
Discussion
The data collected through this Italian public pragmatic
survey revealed that the awareness of obstructive lung
diseases is poor and that minimal differences exist
among age classes. The opinions, beliefs and perspec-
tives on asthma conflict with those on COPD. Asthma
was perceived to be a common and increasingly preva-
lent disease by the majority of people interviewed,
whereas the prevalence of COPD and its increase were
recognised by only approximately 20% of the respon-
dents. The difficulty in identifying individuals who are at
risk for asthma and COPD was recognised by a high
Figure 2 Reasons for adherence: relationship between level of acceptance and latent importance. The upper right side quadrant
represents the reasons for adherence already achieved that need to be maintained; the perspective opportunities represent the reasons for
adherence for which a return of investment is highly probable. The reasons for adherence, located in the left lower quadrant, represent the issues
for which a return of investment is not as probable.
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with some differences, were indicated as responsible for
both asthma and COPD: allergies, pollution and smok-
ing. Awareness of these factors may depend on media
campaigns that have frequently dealt with these themes.
The role of smoking as a cause of disease was recognised
for both asthma and COPD by approximately half of the
respondents. Allergies were considered to be the most
relevant cause of asthma by three out of four respon-
dents, and allergies were also indicated as a factor indu-
cing COPD by 35% of the respondents. Pollution
seemed to be more relevant for asthma than for COPD.
The percentage of patients who claimed to suffer from
asthma and COPD was lower than expected based on
the prevalence of these conditions in Italy, as it has been
estimated that over 3 million families are affected by
these diseases [5,6]. Inhaled drugs were recognised as
the most common treatment for asthma and COPD by
65% of the respondents. Most of the respondents tended
to attribute positive characteristics to the devices with
regard to safety, reliability, effectiveness, ease of use and
practicality. Although approximately 75% of the respon-
dents indicated that an inhaler device is the best solution
for respiratory diseases and 45% believed that inhaler de-
vices could also be useful for other diseases, one-third ofthe respondents believed inhaler devices to be useful pri-
marily for treating milder diseases and administering
mild treatments. Moreover, approximately one-third of
the respondents were unsure of how the device func-
tions; this uncertainty may affect their adherence to
treatment. This issue remains unsatisfactory; only one
out of four individuals used the therapy regularly. These
results are in line with data collected in clinical studies
[13,17,29]. Approximately nine patients out of 10 stated
that their physician provided an adequate explanation
regarding the inhalation technique. However, data have
also emerged from several studies that evaluated the oc-
currence of errors during inhaler device usage; a high pro-
portion of patients do not have the competence to use
their device effectively because they have forgotten what
they were taught and no longer apply the correct tech-
nique that they were trained to use [30]. For this reason,
international guidelines for asthma and COPD manage-
ment state that inhalation technique should be assessed
regularly and corrected if it is inadequate [11,12].
An increased rate of inhalation mistakes could be
caused by device switches that are not supported by
proper patient education. Although they prefer to main-
tain the same device when a change in dose or drug is
necessary, device users must be informed about how a
Figure 3 Barriers for adherence: relationship between level of acceptance and latent importance. The lower right side quadrant
represents the barriers for adherence already contrasted that need to be maintained; the fundamental criticalities represent the barriers for
adherence for which a return of investment is highly probable. The barriers for adherence, located in the left upper quadrant, represent the issues
for with a return of investment is not as probable.
Table 2 Significant differences in answers between sufferers (S) and non-sufferers (NS) and interviewees aged ≤64 and
>64 years
I agree
S NS χ2 p
Motivation
I would be willing to use the inhaler device for a long period for therapies
that last several months
75.5 60 11.8613 p < 0.0027
Using the inhaler device makes it easier to follow a treatment 84 72.1 10.8456 p < 0.0044
Fear
Using the inhaler device ensures that you always take the same dose of the drug 80.8 71.8 13.0236 p < 0.0015
I fear that the dispenser may contain environmentally harmful substances 34.8 21.8 11.5824 p < 0.0031
I think that a drug taken through an inhaler device is more effective 77.1 67.4 10.8163 p < 0.0045
Sense of security I think that a drug taken through an inhaler device has a more prolonged
effect over time
60.2 49.1 9.6056 p < 0.0082
≤64 >64 χ2 p
Trust
I feel totally able to correctly use an inhaler device 80.6 70.6 21.6091 <0.0001
I feel totally able to make an inhaler device work 81.2 72.4 20.0434 <0.0001
The inhaler device seems to be an absolutely safe device 81.2 73.8 12.3264 <0.0021
Availability I would only be willing to use the inhaler device for a short period of time 58.2 53.2 12.2936 <0.0021
Fear Using the inhaler device introduces a risk of taking a very low dose of the drug 24.3 28.5 10.2285 <0.0060
χ2 Chi-square.
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their physician. The need for a real partnership is
underlined by most patients as a fundamental step dur-
ing the switching of any device [31,32].
Compared with people who have never used an inhaler
device, sufferers from asthma or COPD are more
confident on inhaler device use, show less fear and show
a greater sense of security, reliability and trust in this
treatment option. People older than 64 years showed less
attention to device properties than younger people.
Conclusions
In conclusion, the awareness of asthma and COPD is
unsatisfactory; despite their prevalence, these pathologies
remain relatively unknown, and their management in
sufferers appears to be far from ideal. One finding that
emerges from this study is that inhaled drugs are
recognised as the best solution for asthma and COPD
because they offer positive characteristics of safety and
usability. The public opinion that by these devices can
only be used treat mild diseases with weak therapies
should be addressed. The possibility that switching be-
tween devices could be associated with mistakes in drug
consumption and a decrease in treatment adherence
must be addressed by a proper educational plan.
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